Low Clinician Adherence Reported for Hepatitis C, HIV Guidelines
Clinician adherence to screening protocols for patients with hepatitis B (HBV), as well as to treatment guidelines for those with hepatitis C virus (HCV) is suboptimal.
Hepatitis
Viral Hepatitis and Psychiatric Disorders in Adults, Youths
Hepatitis viruses are associated with a higher risk for psychiatric conditions in both adults and children.
Switching TDF to TAF in Chronic Hepatitis B Is Effective, Improves Bone, Renal, and Kidney Function
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF) is safe and effective in patients with chronic hepatitis B (HBV) and was linked to improvements in bone, renal, and kidney function.
Opportunities to Improve Hepatitis A and Hepatitis B Vaccination Coverage
Two studies on hepatitis A and hepatitis B vaccination highlight opportunities to improve coverage of ≥2 doses of hepatitis A vaccine in children and hepatitis B vaccine series completion in adults.
Demographic Shifts in Hepatitis E and Hepatitis C Infection
Hepatitis E seropositivity is higher in older adults and may represent an increased exposure risk over time; in contrast, the opioid crisis has caused a demographic shift in hepatitis C infection, which is now a predominately millennial disease.
Thirty-Two Drinking Water-Related Outbreaks of Hepatitis A From 1971 to 2017
The last four reported hepatitis A outbreaks during 1995 to 2009 were due to individual water systems
FDA: Cases of Serious Liver Injury Reported With Certain HCV Agents
The FDA is warning healthcare professionals that cases of liver decompensation, including liver failure and death, have been linked to certain hepatitis C drugs.
Direct-Acting Antiviral Therapy Benefits Patients With HCV and HCC
Direct-acting antiviral therapy may be a beneficial therapy for patients infected with HCV with a history of hepatocellular carcinoma by increasing overall survival.
Peginterferon Lambda Receives Breakthrough Treatment Status for Hepatitis D
The FDA has granted Breakthrough Therapy designation to peginterferon lambda (Lambda; Eiger BioPharmaceuticals) for the treatment of hepatitis delta virus (HDV) infection.
Less Than One-Third of At-Risk Adults Have Protective Hepatitis B Antibodies
Data published in Clinical Infectious Diseases revealed that by 2014, less than one-third of individuals aged 18 to 49 years who were at risk for hepatitis B virus (HBV) exhibited hepatitis B surface antibody levels indicative of protection (anti-HBs >10 mIU/mL). Data from the 2003 to 2014 National Health and Nutrition Examination Surveys were used…
Next post in Hepatitis
